When the U.S. CDC and FDA recently removed several webpages and datasets from their websites in compliance with a directive from the Office of Personnel Management, they broke the law and harmed ...

As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the ...

Chinese biotechs are increasingly seeking deals with multinational companies, and those deal structures are getting more creative. The “newco” deal structure is getting a lot of attention, but the ...

Newco Akribion Therapeutics GmbH has raised €8 million (US$8.3 million) in a seed round to develop a new and potent class of RNA-targeted CRISPR nucleases, which, rather than cleaving specific nucleic ...

Spinal cord injury (SCI) is a condition affecting the central nervous system characterized by both motor and sensory impairment. SCI causes lipid accumulation in the form of lipid droplets, which may ...

Europe has more oncology startups than the U.S., but many more U.S. companies scale up to the later growth stage. Given the ...

Touting its novel approach for treating glaucoma, Qlaris Bio Inc. reported promising top-line data from two phase II studies testing QLS-111 in patients with primary open-angle glaucoma and ocular ...

Cour Pharmaceuticals Development Co. Inc. has obtained IND clearance from the FDA for CNP-103, a nanoparticle in development to address the underlying autoimmunity of type 1 diabetes. A first-in-human ...

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer, autoimmune ...

Researchers from Sun Yat-sen University and affiliated organizations published data from a study that aimed to assess the role of the TNF receptor-associated factor 6 (TRAF6), E3 ubiquitin ligase ...

Auron Therapeutics Inc. has received FDA clearance of its IND application for its oral KAT2A/B degrader AUTX-703 in hematological malignancies. A phase I proof-of-concept trial in acute myeloid ...

Researchers from the University College Cork have described the neuroprotective effect of TMP-269, a class-IIa-specific histone deacetylase (HDAC) inhibitor in preclinical models of PD. Pan-inhibitors ...